Atrial Fibrillation Recurrence Following Cardioversion: the Role of Clinical Factors and Alpha Defensin Levels
NCT ID: NCT04155879
Last Updated: 2019-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
300 participants
INTERVENTIONAL
2019-11-30
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF
NCT02582190
the Role of Ivabradine in Causing AF in Patients With Chronic Coronary Syndrome
NCT05168189
Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients
NCT04128878
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease
NCT06556732
Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy
NCT00281255
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
Cardioversion without treatment with Colchicine
No interventions assigned to this group
Treatment group
This arm will undergo cardioversion followed by Colchicine (0.5 mg 2x per day) for six months
Colchicine Tablets
Administration of Colchicine at a dose of 0.5mg 2x a day for six months.
Cardioversion
Electrical or pharmacologic restoration of sinus rhythm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Colchicine Tablets
Administration of Colchicine at a dose of 0.5mg 2x a day for six months.
Cardioversion
Electrical or pharmacologic restoration of sinus rhythm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Candidate for cardioversion
Exclusion Criteria
* Hepatic or renal failure
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hillel Yaffe Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hillel Yaffe Medical Center
Hadera, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HYMC-19-0074
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.